This prospective study aimed to evaluate the relationship between HER2 low expression and clinical outcomes in HR‐positive/HER2‐negative MBC patients receiving ET combined with or without CDK4/6 inhibitors, and hopefully to help the clinician select personalized treatment strategies for HR‐positive HER2‐low BC patients. The gene discussed is CDK4; the disease is breast cancer.